Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.1% – Here’s Why

Structure Therapeutics Inc. (NASDAQ:GPCR) traded down 6.1% during trading on Thursday . The stock traded as low as $21.30 and last traded at $21.20. 227,654 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 837,960 shares. The stock had previously closed at $22.57.

Analysts Set New Price Targets

Several research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating for the company. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. Finally, JMP Securities reiterated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Trading Down 3.4 %

The company has a market capitalization of $1.25 billion, a PE ratio of -29.47 and a beta of -2.37. The stock has a fifty day moving average of $24.99 and a two-hundred day moving average of $32.03.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Equities analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently modified their holdings of the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Structure Therapeutics in the 4th quarter worth approximately $34,000. FNY Investment Advisers LLC purchased a new position in Structure Therapeutics in the 4th quarter worth approximately $40,000. Finally, Virtus ETF Advisers LLC increased its stake in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after purchasing an additional 455 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.